- Home
- GYRE vs JBGS Comparison
GYRE vs JBGS Comparison
Compare GYRE & JBGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- JBGS
- Stock Information
- Founded
- GYRE 2002
- JBGS 2016
- Country
- GYRE United States
- JBGS United States
- Employees
- GYRE N/A
- JBGS N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- JBGS Real Estate Investment Trusts
- Sector
- GYRE Health Care
- JBGS Real Estate
- Exchange
- GYRE Nasdaq
- JBGS Nasdaq
- Market Cap
- GYRE 1.3B
- JBGS 1.4B
- IPO Year
- GYRE N/A
- JBGS 2017
- Fundamental
- Price
- GYRE $13.12
- JBGS $15.17
- Analyst Decision
- GYRE
- JBGS Sell
- Analyst Count
- GYRE 0
- JBGS 1
- Target Price
- GYRE N/A
- JBGS $17.00
- AVG Volume (30 Days)
- GYRE 53.3K
- JBGS 503.3K
- Earning Date
- GYRE 11-13-2024
- JBGS 10-29-2024
- Dividend Yield
- GYRE N/A
- JBGS 4.61%
- EPS Growth
- GYRE N/A
- JBGS N/A
- EPS
- GYRE N/A
- JBGS N/A
- Revenue
- GYRE $105,033,000.00
- JBGS $567,034,000.00
- Revenue This Year
- GYRE $25.32
- JBGS N/A
- Revenue Next Year
- GYRE $12.95
- JBGS N/A
- P/E Ratio
- GYRE N/A
- JBGS N/A
- Revenue Growth
- GYRE N/A
- JBGS N/A
- 52 Week Low
- GYRE $8.26
- JBGS $13.04
- 52 Week High
- GYRE $30.40
- JBGS $18.86
- Technical
- Relative Strength Index (RSI)
- GYRE 41.11
- JBGS 24.62
- Support Level
- GYRE $13.07
- JBGS $16.73
- Resistance Level
- GYRE $19.00
- JBGS $17.58
- Average True Range (ATR)
- GYRE 1.16
- JBGS 0.59
- MACD
- GYRE -0.21
- JBGS -0.25
- Stochastic Oscillator
- GYRE 7.39
- JBGS 7.54
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in and develops real estate assets concentrated in urban infill submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to the legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily and third-party asset management and real estate services. The company generates majority of its revenue from Commercial segment.